Welcome. I'm Dr. Vinay Prasad. I'm a hematologist, oncologist, and I'm associate professor of medicine at the University of California, San Francisco. In my professional life, I see patients, I teach trainees, and I do research in health care policy. This is Plenary Session. Plenary session is a

podcast at the intersection of medicine, oncology, and health policy, and you're listening to

Season 3. On this week's episode. This week on Plenary Session, I'm back with the Beat AML

Master Trial. You won't want to miss this discussion.

This is what you've been waiting for.

Beat AML.

Did they beat it?

You'll learn on this week's episode.

If you like this podcast and want more content, follow me on Twitter at V-Prasad MDMPH.

Check out the YouTube channel, Vinay Prasad, MDMPH.

Patreon backers will get access to the slides for lectures I give on plenary session.

Want to hear from us?

Email us your question at plenary session podcast at gmail.com.

All right, this week's episode is the new Nature Medicine paper, Precision Medicine Treatment

and Acute Myeloid leukemia using prospective genomic profiling, feasibility, and preliminary

efficacy of the beat AML master trial.

First thing, you know, on this podcast, I'm always critical of who wrote the paper,

and guess who wrote this paper?

Actually, the authors wrote this paper, Amy Bird, Amy S. Rupert and John C. Bird,

the first, third, and last author are credited with writing this paper. So hats off to them.

You know, this is what we should see more often. When people put their name, particularly in the

first or last position of a manuscript, they should probably write it. It's kind of the standard

...